FBRX Forte Biosciences, Inc.
Forte Biosciences, Inc. (FBRX) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.90 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.1% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Forte Biosciences, Inc.
Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California.
Sector
Healthcare
Industry
Biotechnology